Kura Oncology Stock Probability of Future Stock Price Finishing Over 10.71
| KURA Stock | USD 9.01 0.04 0.45% |
Kura |
Kura Oncology Target Price Odds to finish over 10.71
The tendency of Kura Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 10.71 or more in 90 days |
| 9.01 | 90 days | 10.71 | about 90.12 |
Based on a normal probability distribution, the odds of Kura Oncology to move over $ 10.71 or more in 90 days from now is about 90.12 (This Kura Oncology probability density function shows the probability of Kura Stock to fall within a particular range of prices over 90 days) . Probability of Kura Oncology price to stay between its current price of $ 9.01 and $ 10.71 at the end of the 90-day period is about 5.77 .
Given the investment horizon of 90 days Kura Oncology has a beta of 0.0216. This indicates as returns on the market go up, Kura Oncology average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Kura Oncology will be expected to be much smaller as well. Additionally Kura Oncology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Kura Oncology Price Density |
| Price |
Predictive Modules for Kura Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Kura Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Kura Oncology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Kura Oncology is not an exception. The market had few large corrections towards the Kura Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Kura Oncology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Kura Oncology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.13 | |
β | Beta against Dow Jones | 0.02 | |
σ | Overall volatility | 3.78 | |
Ir | Information ratio | -0.22 |
Kura Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Kura Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Kura Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Kura Oncology generated a negative expected return over the last 90 days | |
| Kura Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (152.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kura Oncology currently holds about 450.26 M in cash with (124.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73. | |
| Kura Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: Head and Neck Cancer Treatment Market 2034 FDA Approval, Clinical Trials, Epidemiology, and Companies by DelveInsight |
Kura Oncology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Kura Stock often depends not only on the future outlook of the current and potential Kura Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kura Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 73.2 M | |
| Cash And Short Term Investments | 424 M |
Kura Oncology Technical Analysis
Kura Oncology's future price can be derived by breaking down and analyzing its technical indicators over time. Kura Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Kura Oncology. In general, you should focus on analyzing Kura Stock price patterns and their correlations with different microeconomic environments and drivers.
Kura Oncology Predictive Forecast Models
Kura Oncology's time-series forecasting models is one of many Kura Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Kura Oncology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Kura Oncology
Checking the ongoing alerts about Kura Oncology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Kura Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Kura Oncology generated a negative expected return over the last 90 days | |
| Kura Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (152.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kura Oncology currently holds about 450.26 M in cash with (124.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73. | |
| Kura Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: Head and Neck Cancer Treatment Market 2034 FDA Approval, Clinical Trials, Epidemiology, and Companies by DelveInsight |
Check out Kura Oncology Backtesting, Kura Oncology Valuation, Kura Oncology Correlation, Kura Oncology Hype Analysis, Kura Oncology Volatility, Kura Oncology History as well as Kura Oncology Performance. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.35) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.